Consumers' absolute and proportional spending on prescription drugs will continue to decline through 2017, but out-of-pocket expenses will then grow to $47.3 billion by 2022, the CMS predicts. The share paid under employer-sponsored drug plans will drop as the share paid by Medicare, Medicaid and exchange-bought plans rises.

Full Story:
Drug Channels

Related Summaries